Abstract 4232
Background
Pediatrics and AYA patients with cancer care often reported to receive high intensity medical care at the end-of-life. Especially, one study showed that Taiwanese children are more likely to receive high intensity care within one month from death than Canadian children. In this study, we investigate the current condition of end-of-life care for pediatrics, AYA patients who died at the hospital in Japan.
Methods
Using a multicenter administrative claims database, we identified patients with cancer aged 17 years or younger who died in hospital between July 2012 and March 2017 from 303 acute care hospitals in Japan. Patients’ data included age, gender, diagnosis, length of stay (LOS), use of opioids, the factors related to high-intensity end-of-life care (H-EOL), which comprised factors as follows; iv chemotherapy within 14 days from death, intensive care unit admission, more than one emergency department (ED) visit, more than 14 days hospital admission, and respiratory ventilation within one month from death.
Results
A total of 106 patients who died in 47 hospitals were included. The median age was 9 (0-17) years old and 57 patients (54%) were boys. Patients had brain tumor (n = 37), solid tumor (n = 30), hematologic malignancy (n = 25), other (n = 14). The average LOS was 60 (0-428 days). Fifty-five patients received opioids within 2weeks before their death. Ten patients received home medical care treatment before their death in the hospitals. Iv chemotherapy within 14 days from death was 25 patients (23.6%), intensive care unit admission within one month from death was 17 patients (16.0%), more than one ED visit within one month from death was 70 patients (66.0%), more than 14 days hospital admission was 69 patients (65.0%), and respiratory ventilation within one month from death was 20 patients (18.9%). Forty patients received one, 49 patients received two, 10 patients received three, 5 patients received four H-EOL care factors, respectively. Totally, 98% of patients had at least one H-EOL care factor.
Conclusions
Our study clarified the current situation of end-of-life care in the field of pediatrics, AYA with cancer. The proportion of H-EOL care in Japan is similar to that in Taiwan, and higher compared with that in Canada.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5011 - LCSCAF1 maintains cancer stem-like traits by stabilizing c-Myc protein and promotes metastasis and recurrence in lung cancer
Presenter: Tao Guo
Session: Poster Display session 1
Resources:
Abstract
4955 - XAF1 Enhances Temozolomide Induced Autophagic Cell Death through AMPK signaling pathway
Presenter: Mingoo Lee
Session: Poster Display session 1
Resources:
Abstract
5616 - The effect of cortisol on methylation patterns in breast cancer cell lines
Presenter: Haya Intabli
Session: Poster Display session 1
Resources:
Abstract
4649 - Global and sex-specific epigenome-wide association studies for the identification of the main methylated loci related to smoking in a Mediterranean population
Presenter: Judith Begona Ramirez Sabio
Session: Poster Display session 1
Resources:
Abstract
4984 - Whole transcriptomics analyses of mimicking Circulating Tumor Cells (CTCs) by single-cell RNA sequencing (scRNAseq)
Presenter: Jessica Garcia
Session: Poster Display session 1
Resources:
Abstract
5926 - Comparison of enzymatic- and bisulfite conversion to map the plasma cell-free methylome in cancer
Presenter: Nicole Lambert
Session: Poster Display session 1
Resources:
Abstract
5454 - Detection of low mutations in hepatocellular carcinoma by using circulating tumor DNA
Presenter: Esl Kim
Session: Poster Display session 1
Resources:
Abstract
4428 - Variants in the JAK1 and JAK2 genes in the risk and prognosis of patients with cutaneous melanoma
Presenter: Bruna Carvalho
Session: Poster Display session 1
Resources:
Abstract
4409 - P-Rex1 expression in breast cancer patients.
Presenter: Angela Lara Montero
Session: Poster Display session 1
Resources:
Abstract
4185 - Modulation of Risk of Cutaneous Melanoma Patients by Variants in STAT3 Gene and Functional Analysis
Presenter: Gabriela Gomez
Session: Poster Display session 1
Resources:
Abstract